DrugPatentWatch Database Preview
RITUXAN Drug Profile
Summary for Tradename: RITUXAN
| Patents: | 651 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RITUXAN |
Pharmacology for RITUXAN
| Mechanism of Action | CD20-directed Antibody Interactions |
US Patents for RITUXAN
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | ➤ Sign Up | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | ➤ Sign Up | RX | search | |
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | ➤ Sign Up | Pharmacyclics LLC (Sunnyvale, CA) | ➤ Sign Up | RX | search | |
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | ➤ Sign Up | Array BioPharma Inc. (Boulder, CO) | ➤ Sign Up | RX | search | |
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | ➤ Sign Up | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | ➤ Sign Up | RX | search | |
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | ➤ Sign Up | YALE UNIVERSITY (New Haven, CT) | ➤ Sign Up | RX | search | |
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | ➤ Sign Up | VentiRx Pharmaceuticals, Inc. (Seattle, WA) | ➤ Sign Up | RX | search | |
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | ➤ Sign Up | KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) | ➤ Sign Up | RX | search | |
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Patent Expiration | Status | Orphan | Source |
International Patents for RITUXAN
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Denmark | 2278003 | ➤ Sign Up |
| Eurasian Patent Organization | 200800002 | ➤ Sign Up |
| Japan | 6118273 | ➤ Sign Up |
| Hong Kong | 1195311 | ➤ Sign Up |
| Slovenia | 2361251 | ➤ Sign Up |
| Canada | 2899811 | ➤ Sign Up |
| Cyprus | 1115695 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for RITUXAN
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 00140 | Estonia | ➤ Sign Up | |
| CA 2016 00056 | Denmark | ➤ Sign Up | PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530 |
| 273 5026-2016 | Slovakia | ➤ Sign Up | PRODUCT NAME: IBRUTINIB VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/945 20160530 |
| PA2015031 | Lithuania | ➤ Sign Up | PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| LUC00050 | Luxembourg | ➤ Sign Up | PRODUCT NAME: SARILUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (KEVZARA); AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627 |
| 122017000015 | Germany | ➤ Sign Up | PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703 |
| CA 2018 00020 | Denmark | ➤ Sign Up | PRODUCT NAME: AFUCOSYLERET ANTISTOF, DER BINDER TIL ALFA-UNDERENHEDEN AF DEN HUMANE INTERLEUKIN-5-RECEPTOR, SAERLIGT BENRALIZUMAB ELLER EN TERAPEUTISK AEKVIVALENT VARIANT DERAF, SOM ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/17/1252 20180110 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
